benralizumab

03/01/2023 - "Benralizumab is highly effective in many, but not all, patients with severe asthma. "
09/01/2020 - "In conclusion, our results suggest that via its anti-eosinophil actions benralizumab improved airflow limitation, lung hyperinflation, and respiratory symptoms, as well as lowered asthma exacerbation rate and abrogated OCS consumption in most patients."
02/25/2024 - "Conclusions: Benralizumab was shown to be very effective in a patient with late-onset severe eosinophilic asthma presenting features of chronic obstructive disease-habitual exposure to tobacco and inhaled noxious substances, and persistent airflow limitation on spirometry."
06/28/2023 - "Benralizumab treatment resulted in a marked improvement in asthma control, suppressed blood eosinophil levels and reduction in the number of exacerbations in the subgroup of patients with severe eosinophilic asthma and nasal polyposis. "
01/01/2023 - "Benralizumab induction resulted in a marked decrease in blood and sputum eosinophil levels and a significant improvement in asthma symptoms, quality of life scores, FEV1, and exacerbation frequency. "

09/01/2023 - "After benralizumab administration he demonstrated improvement in his left ventricular ejection fraction, normalization of his right ventricular function, and improvement in symptoms with resolution of his hypereosinophilia. "
05/01/2021 - "A treatment trial with benralizumab was more successful and led to suppression of airway eosinophilia. "
03/06/2021 - "Further clinical studies are warranted to determine whether benralizumab or other drugs targeted against IL-5/IL-5R may be useful in managing multiple conditions associated with eosinophilia."
01/01/2024 - "Mean eosinophilia at baseline was 1103.57 cells/mcL (SD 604.88; minimum-maximum 460-2400); after the use of benralizumab, the count dropped to zero. "
01/01/2022 - "Benralizumab treatment completely depleted blood and GI tissue eosinophilia in patients with eosinophilic GI disorders, but clinical response, while encouraging, was heterogeneous. "

08/01/2023 - "Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA)."
05/15/2023 - "Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy."
01/01/2022 - "Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis."
01/01/2022 - "Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis."
03/01/2024 - "Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis."

12/01/2020 - "The proportion of patients who achieved successful switching to benralizumab was higher in patients with eosinophilic chronic rhinosinusitis (ECRS) than in those without (76.9 vs. 20.0%; p = 0.025). "
05/07/2024 - "We investigated the pharmacokinetic and pharmacodynamic effects of benralizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) from the phase III OSTRO trial. "
05/07/2024 - "Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial."
01/01/2022 - "Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial."
01/01/2021 - "Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial."

01/01/2019 - "In this small phase 2 trial, patients with PDGFRA-negative hypereosinophilic syndrome who received benralizumab for 12 weeks had lower absolute eosinophil counts than those who received placebo. "
01/01/2021 - "Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome."
01/01/2021 - "Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient."
01/01/2019 - "Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome."
01/01/2022 - "Although benralizumab proved clinically efficacious in clinical trials for patients with severe asthma and hypereosinophilic syndrome, in-depth characterisation of its anti-eosinophilic mechanisms of action remains elusive. "